Spots Global Cancer Trial Database for Neoadjuvant Compound 121564 Plus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Neoadjuvant Compound 121564 Plus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
Official Title: Phase II Trial of Neoadjuvant Compound 121564 Plus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
Study ID: NCT03480230
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to assess the response rate to neoadjuvant Compound 121564 plus platinum doublet chemotherapy in patients with early stage non-small cell lung cancer.
Detailed Description: Open-label, single-arm multi-center phase II trial of neoadjuvant Compound 121564 plus platinum doublet chemotherapy conducted among patients with early stage (IB, II, IIIA) non-small cell lung cancer.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
King Hussein Cancer Center, Amman, , Jordan
American University of Beirut Medical Center, Beirut, , Lebanon
Bellevue Medical Center, Beirut, , Lebanon
Lebanese American University Medical Center-Rizk Hospital, Beirut, , Lebanon
Hammoud Hospital University Medical Center, Sidon, , Lebanon
Contact Details
Name: Arafat H Tfayli, MD
Affiliation: American University of Beirut Medical Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
